Fig. 5
From: Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
cFAM124A is the best marker to predict the ability of K-80003 to promote AG sensitivity in PDAC. A-B, Representative multiplex IHC staining for cFAM124A, p-Akt (Thr308), and p-Akt (Ser473) expression in PDAC tissues collected from K-80003 responsive and K-80003 non-responsive groups. Quantification of cFAM124A, p-Akt (Thr308), and p-Akt (Ser473) staining in PDAC tissues collected from K-80003 responsive and K-80003 non-responsive groups. Scale bar, 100 μm. C-D, Representative H&E, FISH staining for cFAM124A, and IHC staining for p-Akt (Thr308) and p-Akt (Ser473) in PDAC tissues collected from K-80003 responsive and K-80003 non-responsive groups. Quantification of cFAM124A, p-Akt (Thr308), and p-Akt (Ser473) staining in PDAC tissues collected from K-80003 responsive and K-80003 non-responsive groups. Scale bar, 100 μm. E-F, Representative H&E, FISH staining for cFAM124A and IHC staining for p-Akt (Thr308) and p-Akt (Ser473) in paracancer tissues collected from K-80003 responsive and K-80003 non-responsive groups. Quantification of cFAM124A, p-Akt (Thr308), and p-Akt (Ser473) staining in paracancer tissues collected from K-80003 responsive and K-80003 non-responsive groups. Scale bar, 100 μm. G, Fold changes in cFAM124A, p-Akt (Thr308) and p-Akt (Ser473) expression levels in PDAC tissues collected from K-80003 responsive and K-80003 non-responsive groups. H, Peak fold changes in cFAM124A, p-Akt (Thr308), and p-Akt (Ser473) expression in different groups. Not significant (ns), *P < 0.05; **P < 0.01; ***P < 0.001)